Open Actively Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

About

Brief Summary

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
23-5275
Category
Autoimmune Disorders
Contact
Ross Divinagracia
Location
  • UCLA Santa Monica
  • UCLA Westwood
For Providers
NCT No.
NCT06143878
For detailed technical eligibility, visit ClinicalTrials.gov.